CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

Bookmark and Share
Published: 13 Jun 2020
Views: 1171
Rating:
Save
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Prof Katja Weisel speaks to ecancer about the phase III CANDOR study that she presented at the virtual EHA 2020 conference.

She details the design of the study which looked at the combination of carfilzomib, dexamethasone and daratumumab (KdD) versus carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM).

Prof Weisel also explains patients were grouped according to categories based on prior lines of therapy and types of therapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

The CANDOR study, basically from the study design, was a 2-to-1 randomised trial. Patients were included when they were adult and had first to third relapse of multiple myeloma and who were eligible and were then randomised between carfilzomib, daratumumab and dexamethasone, the KdD regimen, versus carfilzomib and dexamethasone, the Kd regimen.

The hazard ratio for PFS was comparable between patients with one prior therapy and those with two or more prior therapies. For the analysis by previous lenalidomide treatment patients were grouped into categories of lenalidomide exposed or naïve and lenalidomide refractory or non-refractory and the hazard ratio for PFS was comparable between the lenalidomide exposed and refractory subgroups but the observed PFS difference was lower in the lenalidomide naïve subgroup. For the analysis by previous bortezomib treatment patients were grouped into categories of bortezomib exposed or naïve and bortezomib refractory or non-refractory and the hazard ratio for PFS was comparable across the bortezomib exposed, naïve and non-refractory subgroups but the observed PFS difference was lower in the bortezomib refractory subgroup. This overall showed that the benefit-risk profile of KdD compared with Kd was generally consistent across subgroups regardless of the number of prior lines and prior treatment with lenalidomide or bortezomib.